Prostane

Ingredients:

Salep orchid (Orchis mascula L.) tuber
Hygrophila (Astercantha longifolia Nees.) seed
Lettuce (Lactuca scariola L.) seed
Cow-itch (Mucuna pruriens (L.)DC.) seed
Elephant creeper (Argyreia speciosa [L. f.] Sweet) root
Small caltrops (Tribulus terrestris L.) fruit
Jeevanti (Leptandenia reticulataW. & A.) whole
Stone flower [Parmelia perlata (Huds.) Ach.] whole

Prostane® is manufactured by The Himalaya Drug Company in
India and distributed in the United States by Himalaya USA. Each
tablet contains 600 mg of a proprietary blend of eight herbs. Prostane
is also sold as ProstaCare®. The product is called “Speman” in the
clinical trial we reviewed. Unfortunately that trial did not include any
details on the product, so we were unable to compare the material
used in the trial to the current product.


We reviewed one study with Prostane for treatment of acute and
chronic urinary retention due to prostate enlargement. A nonmalignant
enlargement of the prostate that is common in men older than 40
years of age is called benign prostatic hyperplasia (BPH). Symptoms
of BPH include increased urinary urgency and frequency, urinary
hesitancy, intermittency, sensation of incomplete voiding, and decreased
force of the urine stream.


Benign Prostatic Hyperplasia

An open, placebo-controlled study with Prostane included 55 men
with acute and chronic urinary retention due to prostate enlargement.
Forty-seven participants had BPH, six had fibrotic disease, and two
had prostate cancer. Forty-five of the patients were treated with
Prostane and ten served as controls. Approximately 74 percent (28 of
38) of those in the treatment group with BPH had improved symptoms
and decreases in prostate size and urinary congestion after 10 to
14 days of treatment with two tablets three times daily. The other ten
in the treatment group with BPH required surgery (prostatectomy).
All men that served as controls required surgery (Mukherjee, Ghosh,
and De, 1986). The clinical efficacy of Prostane in this study was
rated as undetermined due to poor study design.


No side effects were reported in a clinical trial with 45 subjects
given two tablets three times daily for a month (Mukherjee, Ghosh,
and De, 1986).